Skip to main content

Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions

Written by Customer Service on . Posted in Public Companies.

Event Sponsored by BioXcel Therapeutics Set for 10 a.m. EST on Monday, Dec. 8

Topics Covered by Drs. Leslie Citrome, Marc Milano, and Leon Ravin to Include Opportunities and Advantages of Self-Administered Treatments at Home

NEW HAVEN, Conn., Dec. 03, 2025 (GLOBE NEWSWIRE) — As millions of patients and caregivers continue to struggle with acute agitation episodes associated with bipolar disorder and schizophrenia, a timely and highly anticipated virtual roundtable will bring together leading medical experts to discuss the future of care, including the growing potential for safe, effective self-administered treatments at home.

Hosted by Anjalee Khemlani, an award-winning healthcare journalist known for her in-depth reporting at Yahoo Finance and NJBIZ, the one-hour event will take place Monday, Dec. 8, at 10 a.m. EST. Pre-registration is now open at the following link: https://event.webcasts.com/starthere.jsp?ei=1744467&tp_key=14d071615e.

With an estimated 57 to 77 million episodes of agitation associated with bipolar disorders and schizophrenia in the at-home setting occurring annually in the U.S., this roundtable aims to give clinicians, caregivers, investors, and healthcare professionals an inside look at how treatment paradigms are shifting, and what innovations may soon redefine patient care outside emergency rooms, psychiatric facilities, and skilled nursing settings.

The roundtable participants are:

  • Marc A. Milano, M.D., FACEP, Chair, Department of Emergency Medicine at Newark Beth Israel Medical Center and Children’s Hospital of New Jersey
  • Leon Ravin, M.D., Psychiatrist and Statewide Psychiatric Medical Director for the Division of Public and Behavioral Health, State of Nevada

Attendees may ask questions via written Q&A. A recording of the event will be posted to the BioXcel Therapeutics website and available here.

About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com.

Contact Information:

Corporate/Investors
Russo Partners
Nic Johnson
nic.johnson@russopartnersllc.com
1.303.482.6405

Media
Russo Partners
David Schull
david.schull@russopartnersllc.com
1.858.717.2310

Source: BioXcel Therapeutics, Inc.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.